Aspen Pharmacare Holdings Limited (APNHF) Stock

About Aspen Pharmacare Holdings Limited

Operating worldwide, Aspen Pharmacare Holdings Limited, together with its subsidiaries, focuses on the development, production, and global distribution of specialized and branded pharmaceutical products. The company's business activities are structured into two main divisions: Commercial Pharmaceuticals and Manufacturing. Under its Anaesthetics portfolio, Aspen offers diverse products such as general anesthetics, muscle relaxants, and topical agents. Its Thrombosis brand is dedicated to a variety of injectable anticoagulants, with an emphasis on low molecular weight heparins, Xa inhibitors, and heparin derivatives. Additionally, Aspen provides a range of branded consumer, prescription, and over-the-counter medications through regional brands. These include Circadin (for sleep management), Foxair (for respiratory conditions), Maltofer (an iron supplement), Mybulen (a painkiller), and Zyloric (which controls uric acid production). Beyond its proprietary offerings, the company also manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage form products to external clients. Founded in 1850, Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Limited is headquartered in ZA.

Aspen Pharmacare Holdings Limited (APNHF) stock trades at $8.80 with a market capitalization of $3.91B. The stock is valued at a price-to-earnings (P/E) ratio of -33.17, price-to-book of 0.82, price-to-sales of 1.73. Over the past 52 weeks the stock has ranged between $6.23 and $8.80, and currently trades at its 52-week high. It pays a dividend yielding 1.36%.

On profitability, Aspen Pharmacare Holdings Limited generates a return on equity (ROE) of -2.41%, return on capital employed of 5.49%, an operating margin of 16.01%, a net profit margin of -5.19%.

Official website: www.aspenpharma.com